Apply to trial NCT07284927

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Biological intervention

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening